Oncopeptides AB: CHMP issues a positive opinion recommending

STOCKHOLM, June 23, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological

Related Keywords

France , Germany , Norway , Iceland , Stockholm , Sweden , Netherlands , United Kingdom , Italy , Liechtenstein , Spain , Lichtenstein , Oncopeptides Pepaxti , Annika Muskantor , Rolf Gulliksen , Klaas Bakker , Pieter Sonneveld , Jakob Lindberg , European Medicines Agency , European Commission , Erasmus University Medical Center , Drug Administration , Global Head Of Corporate Communications , Committee For Medicinal Products Human Use , Nasdaq Stockholm , Medicinal Products , Human Use , European Economic Area , Executive Vice President , Chief Medical , Global Head , Corporate Communications , Mid Cap , Oncopeptides , Thmp , Issues , Positive , Opinion , Recommending , Bull , Approval , Epaxti , Patients , Triple , Glass , Refractory , Multiple , Myeloma ,